Paper42469710
Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances.
Luo F and 5 others. BMC Nephrol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances. Papers, record 42469710. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469710
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mineralocorticoid Receptor Antagonists | Major topic |
| Renal Insufficiency, Chronic | Major topic |
| Humans | |
| Renin-Angiotensin System | |
| Naphthyridines | |
| Proteinuria |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZD20240019;GZY-KJS-ZJ-2025-055 | Hangzhou Municipal Health Science and Technology Key Project(grant number:ZD20240019);Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform(grant number:GZY-KJS-ZJ-2025-055);Hangzhou "Two-way Open Bidding" Co-construction Project for Medical Specialty | PubMed |
Source PubMed
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39537335 | Primary glomerular diseases and long-term adverse health outcomes: A nationwide cohort study. | J Intern Med | 2025 | https://conductscience.org/library/papers/39537335 | PubMed |
| 2 | 37875671 | The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/37875671 | PubMed |
| 3 | 18404673 | A comparison of the aldosterone-blocking agents eplerenone and spironolactone. | Clin Cardiol | 2008 | https://conductscience.org/library/papers/18404673 | PubMed |
| 4 | 39907538 | Mineralocorticoid receptor antagonism for non-diabetic kidney disease. | Nephrol Dial Transplant | 2025 | https://conductscience.org/library/papers/39907538 | PubMed |
| 5 | 39248263 | Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor-Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor-p65-Signal Transducer and Activator of Transcription 3 Complex. | J Am Heart Assoc | 2024 | https://conductscience.org/library/papers/39248263 | PubMed |
| 6 | 12167587 | Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na(+) transport. | Am J Physiol Renal Physiol | 2002 | https://conductscience.org/library/papers/12167587 | PubMed |
| 7 | 41005568 | Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis. | Kidney Int | 2025 | https://conductscience.org/library/papers/41005568 | PubMed |
| 8 | 37906287 | Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. | J Clin Invest | 2024 | https://conductscience.org/library/papers/37906287 | PubMed |
| 9 | 38186886 | Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. | Clin Kidney J | 2024 | https://conductscience.org/library/papers/38186886 | PubMed |
| 10 | 41206667 | Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. | Nephrol Dial Transplant | 2026 | https://conductscience.org/library/papers/41206667 | PubMed |
| 11 | 41301427 | Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines. | Biomolecules | 2025 | https://conductscience.org/library/papers/41301427 | PubMed |
| 12 | 41332164 | Effect of finerenone on proteinuria reduction in IgA nephropathy. | Ren Fail | 2025 | https://conductscience.org/library/papers/41332164 | PubMed |
| 13 | 36351458 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. | Lancet | 2022 | https://conductscience.org/library/papers/36351458 | PubMed |
| 14 | 22301619 | Inducible kidney-specific Sgk1 knockout mice show a salt-losing phenotype. | Am J Physiol Renal Physiol | 2012 | https://conductscience.org/library/papers/22301619 | PubMed |
| 15 | 26361797 | Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. | J Am Soc Nephrol | 2016 | https://conductscience.org/library/papers/26361797 | PubMed |
| 16 | 40366120 | Spironolactone protects against hypertension-induced renal fibrosis by promoting autophagy and inhibiting the NLRP3 inflammasome. | J Hypertens | 2025 | https://conductscience.org/library/papers/40366120 | PubMed |
| 17 | 41573738 | Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41573738 | PubMed |
| 18 | 29548765 | The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. | Kidney Int | 2018 | https://conductscience.org/library/papers/29548765 | PubMed |
| 19 | 42171960 | Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/42171960 | PubMed |
| 20 | 41351406 | Aldosterone-Induced Renal Lymphangiogenesis and Endothelial-To-Mesenchymal Transformation to Promote Renal Interstitial Fibrosis Through the MR/TGF-β1 Pathway in Mice. | Front Biosci (Landmark Ed) | 2025 | https://conductscience.org/library/papers/41351406 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| NR3C2 | 4306 | PubTator's text mining | https://conductscience.org/library/genes/4306 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42469710
GET https://conductscience.org/api/papers/v1/42469710/references?page=2